Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced the launch of an inaugural awareness day for anaplastic lymphoma kinase positive (ALK+) metastatic non-small cell lung cancer (NSCLC) patients and their care partners. The awareness day is the first of its kind to specifically focus on ALK+ NSCLC and will be held on November 15th and subsequently on the third Tuesday of each November.
“This year we’re recognizing our 25 year anniversary as a company and we are extremely proud of our research efforts for rare cancers. This inaugural ALK+ Day, a collaborative engagement with the lung cancer patient advocacy community, has the goal to place progress made in the ALK+ NSCLC space within the context of advances made in non-small cell lung cancer research,” stated Timothy P. Clackson, Ph.D., president of research and development and chief scientific officer at ARIAD. “As we engage with the lung cancer community we aim to help raise awareness about ALK+ NSCLC and encourage others to join the conversation about the R&D progress in this rare cancer space, as well as the importance of mutation testing.”
This month, ARIAD seeks to support patient education and community, while also advancing innovative science focused on rare cancers. Through its collaboration with the Lung Cancer Foundation of America (LCFA), the community is encouraged to talk about “The Little Things” that lung cancer patients are thankful for, that their lungs allow them to do, using the social media hashtag #LittleThingsLCFA during the month of November.
“We are excited to work with ARIAD on building awareness about ALK+ non-small cell lung cancer during Lung Cancer Awareness Month in order to highlight the progress and work still-to-be-done in battling lung cancer. Our mission is the dramatic improvement in survivorship of lung cancer patients through the funding of transformative science, with the ultimate goal of curing the disease,” said Kim Norris, president and co-founder of the Lung Cancer Foundation of America.
As part of its ongoing commitment to patients, ARIAD has also launched the Living with ALK website to help patients and caregivers access support, resources, and information for living with ALK+ non-small cell lung cancer.(Original Source)
Shares of Ariad Pharmaceuticals are currently trading at $12.53, up $0.10 or 0.80%. ARIA has a 1-year high of $14.34 and a 1-year low of $4.37. The stock’s 50-day moving average is $13.05 and its 200-day moving average is $9.49.
On the ratings front, Ariad has been the subject of a number of recent research reports. In a report issued on November 8, Cowen analyst Chris Shibutani reiterated a Buy rating on ARIA, with a price target of $16, which represents a potential upside of 29% from where the stock is currently trading. Separately, on November 7, Leerink Swann’s Michael Schmidt reiterated a Buy rating on the stock and has a price target of $20.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Chris Shibutani and Michael Schmidt have a yearly average return of 14.9% and 24.3% respectively. Shibutani has a success rate of 79% and is ranked #322 out of 4209 analysts, while Schmidt has a success rate of 68% and is ranked #21.
Overall, 2 research analysts have rated the stock with a Sell rating, 2 research analysts have assigned a Hold rating and 5 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $12.60 which is 1.4% above where the stock closed last Friday.
ARIAD Pharmaceuticals, Inc. operates as an oncology company, which engages in the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer. Its products include Iclusig and Caregivers.